Portfolio of Cancer Immunotherapy Stocks

Here are 18 cancer immunotherapy stocks.


18 Cancer Immunotherapy Stocks

Name
& Monthly Returns

Symbol
& Snapshot

Recent Prices
& Trendline Chart

AmgenAMGN
AstraZenecaAZN
BeiGene Ltd.BGNE
Bellicum PharmaceuticalsBLCM
bluebird bioBLUE
Bristol-Myers SquibbBMY
Celldex TherapeuticsCLDX
CellectisCLLS
CelyadCYAD
Clovis OncologyCLVS
Compugen Ltd.CGEN
CurisCRIS
CytomX TherapeuticsCTMX
Gilead SciencesGILD
Incyte CorporationINCY
MerckMRK
Nektar TherapeuticsNKTR
NovartisNVS
Sparkline weekly price charts based on Alpha Vantage data.


Portfolio Values

To inspect the performance of the Cancer Immunotherapy Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Alpha Vantage.

All 18 stocks are included in the portfolio computations. The current value of the portfolio assumes that $555.56 was invested in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends.

The current value of the $10,000 investment is $8,674. The percent return is -13.26%. The annualized return is -2.80%.


18 Cancer Immunotherapy Stocks Returns

Name

Symbol

% Return & Details

AmgenAMGN63.50%
AstraZenecaAZN127.11%
BeiGene Ltd.BGNE259.67%
Bellicum PharmaceuticalsBLCM-98.98%
bluebird bioBLUE-93.92%
Bristol-Myers SquibbBMY61.96%
Celldex TherapeuticsCLDX-27.23%
CellectisCLLS-89.04%
CelyadCYAD-95.92%
Clovis OncologyCLVS-98.08%
Compugen Ltd.CGEN-51.32%
CurisCRIS-89.58%
CytomX TherapeuticsCTMX-88.19%
Gilead SciencesGILD5.58%
Incyte CorporationINCY-39.66%
MerckMRK74.35%
Nektar TherapeuticsNKTR-80.56%
NovartisNVS21.72%


Portfolio Value Chart for Last 100 Daily Closes



Related Portfolios

Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks

Portfolio of Biotech Stocks

Portfolio of Immune Checkpoint Inhibitor Stocks